Imanova: investing in know-how
London-based imaging company Imanova develops ‘imaging biomarkers’ to support the business of drug discovery, and takes a novel approach to protecting its innovations. LSIPR spoke to chief executive Kevin Cox about the company’s strategy.
Dolly the sheep: the demise of biotechnology patents
With the Federal Circuit relying on the precedent set by the Prometheus and Myriad decisions, Dolly the sheep has been summarily declared ineligible for patent protection. Nabeela Rasheed sums up the implications.
Subject matter eligibility: interpreting the USPTO guidelines
The new examination guidelines do not carry the weight of law, and it is not likely that their more extreme aspects will withstand judicial scrutiny, but practitioners need to keep tabs on court decisions, says Courtenay C. Brinckerhoff.
Indian patent law: up for a fight
International damage may result from India’s steps to formalise its isolationist patents regime, says Jason Rutt.
Protecting biomarkers and personalised/stratified medicine
With careful patent drafting and prosecution, it is possible to capture significant IP value in the clinically—and commercially—important area of biomarkers, says Stephanie Pilkington of Potter Clarkson.
Patients in a test tube: Horizon Discovery's IP strategy
Horizon Discovery’s cell line-creating technology has the potential to advance personalised medicine. But how does the gene editing company stay competitive in a crowded field? LSIPR found out.
The Copaxone battle: an update
Arguments over the term of the patents granted are at the heart of the Copaxone conflict, says Archana Shanker.
Copyright compliance in the life sciences industry
Many researchers are unaware of the legalities when it comes to sharing and using copyrighted material, but licensing agreements can help, says Kate Alzapiedi of copyright licensing firm RightsDirect.
Myriad v Ambry: the BRCA battle continues
Myriad has failed to stop Ambry offering genetic tests using the BRCA1 or BRCA2 genes, but Ambry raised a substantial question about the validity of the claims of Myriad’s patents, as MaryAnne Armstrong reports.
Virtual organs: cutting drug development risks
Strand Life Sciences’ ‘virtual’ liver could cut the failure rate of drug development by giving researchers a clearer idea which of the potential drugs are unlikely to work. How does the Bangalore-based company protect and license its technology?
